New CBD candidate said to boost bioavailability, expanding therapeutic potential

New CBD candidate said to boost bioavailability, expanding therapeutic potential
Cannabis Health News

A new drug candidate is said to have demonstrated a three to fourfold increase in bioavailability when compared to unmodified CBD. A clinical-stage biotherapeutics company, PureTech Health, says its oral CBD candidate could expand the therapeutic application of the cannabinoid as a treatment for a range of indications. The therapeutic candidate, known as LYT-310, is an oral cannabidiol prodrug which can be administered via a capsule. It is said to have shown a three to fourfold increase in bioavailability compared to unmodified CBD in a preclinical model. Lymphatic-targeting LYT-310 leverages the company’s trademark Glyph technology. Glyph is a synthetic lymphatic-targeting chemistry platform designed to employ the lymphatic system’s natural lipid absorption and transport process to enable the oral administration of certain therapeutics.  Glyph adds a dietary fat molecule to an existing compound so that the drug is re-routed through the lymphatic system, bypassing the liver and instead moving from the gut into the lymphatic vessels that normally process dietary fats.  This lymphatic-targeting chemistry is designed to allow oral availability of certain drugs that are currently delivered via other means. The aim is to retain the validated efficacy whilst improving safety and tolerability.  In multiple preclinical models, including large animal and non-human primate, LYT-310 is said to have demonstrated a three to fourfold increase in oral exposure when compared to unmodified CBD in a fasted state. The company says this has the potential to translate into improved safety and reduced side effects.  Lymphatic transport has also been confirmed in preclinical models, with up to 30% of LYT-310 entering the lymphatics, compared to 5% for unmodified  CBD – which further supports the novel Glyph mechanism of enhancing bioavailability.  Expanding the therapeutic potential of CBD To date, only one CBD-based product, Epidyolex, has received regulatory approval in the US and Europe to treat…

Excerpt only …
READ MORE BELOW
Source : New CBD candidate said to boost bioavailability, expanding therapeutic potential

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.